Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | C1R | P00736 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1621892 | 0.85 | HTR2A (0.42) | C5AR1HTTNPSR1L3MBTL1KDM4E | |
| SCHEMBL3639122 | 0.78 | TNNI3K (0.45) | GAAKMT2AMEN1 | |
| SCHEMBL6831732 | 0.77 | MAPT (0.53) | C5AR1MAPTMCOLN3CA12CA9 | |
| SCHEMBL24125226 | 0.76 | C5AR1 (0.77) | C5AR1MAPTMCOLN3CA12CA9 | |
| SCHEMBL7971332 | 0.71 | GAA (0.50) | MAPTLMNAHTTGAAL3MBTL1 | |
| SCHEMBL6831957 | 0.71 | C5AR1 (0.61) | C5AR1MAPTMCOLN3CA12CA9 | |
| SCHEMBL7150548 | 0.69 | C5AR1 (0.83) | C5AR1MAPTMCOLN3CA12CA9 | |
| SCHEMBL17174235 | 0.69 | MAPT (0.82) | C5AR1MAPTMCOLN3CA12CA9 | |
| SCHEMBL2008337 | 0.69 | MAPT (1.00) | C5AR1MAPTMCOLN3CA12CA9 | |
| SCHEMBL21801997 | 0.68 | NCF1 (0.43) | MAPTGAAKDM4ETSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183232-B1 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2183232-B1 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-7928140-B2 | Benzothiazole PI3 kinase modulators for cancer treatment | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928140-B2 | Benzothiazole PI3 kinase modulators for cancer treatment | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928140-B2 | Benzothiazole PI3 kinase modulators for cancer treatment | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2183232-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | Amgen, Inc (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009017822-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017822-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054405-A1 | PI3 kinase modulators and methods of use | PIK3CA, PIK3C2A, PIK3C2B | C5AR1 785/4885MAPT 4500/4885MCOLN3 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.